Polymorphisms of RAD51G135C and XRCC3C241T genes and correlations thereof with prognosis and clinical outcomes of acute myeloid leukemia

National Medical Journal of China

Volumn 88, Issue 6, 2008, Pages 378-382

  Liu, Liang ^a   Yang, Lin ^a   Zhang, Yue ^a   Xu, Ze Feng ^a   Yu, Ming Hua ^a   Wang, Jian Xiang ^a   Xiao, Zhi Jian ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Acute; Leukemia; Myelocytic; RAD51; XRCC3

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; GUANINE; RAD51 PROTEIN; TYROSINE; XRCC3 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ALOPECIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMATURIA; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; STATISTICAL SIGNIFICANCE; VOMITING; WILD TYPE;

ADOLESCENT; ADULT; AGED; ALLELES; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RAD51 RECOMBINASE; REMISSION INDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 43649099818     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res, 2004, 10: 2675-2680.
2. Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis, 2006, 27: 997-1007.
3. Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood, 2002, 100: 3761-3766.
4. Chinese source.
5. Krajinovic M, Lebuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res, 2002, 8: 802-810.
6. Kuptsova N, Kopecky KJ, Godwin J, et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood, 2007, 109: 3936-3944.
7. Chinese source.
8. Chinese source.
9. Chinese source.
10. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 2003, 21: 4642-4649.
11. Voso MT, D'Alo'F, Putzulu R, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood, 2002, 100: 2703-2707.
12. Naoe T, Tagawa Y, Kiyoi H, et al. Prognostic significance of the null genotype of glutathione S2transferase2T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia, 2002, 16: 203-208.
13. Chinese source.
14. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 2004, 10: 4939-4943.
15. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol, 2004, 15: 1194-1203.
16. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 2004, 44: 311-316.
17. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 2004, 91: 344-354.
18. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol, 2003, 1: 162-166.
19. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res, 2001, 21: 3075-3079.
20. Yoon SM, Hong YC, Park HJ, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys, 2005, 63: 885-891.
21. Berwick M, Matullo G, Song YS, et al. Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma. J Clin Oncol, 2004, 22: 3997-4001.
22. Mehta PA, Alonzo TA, Gerbing RB, et al. XPD Lys751gln polymorphism: etiology and outcome of childhood acute myeloid leukemia. A children's oncology group report. Blood, 2006, 107: 39-45.